Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine

GS-236-0123
Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine GS-236-0123: Design

Study Design: GS-236-0123

- **Background**: Open-label, randomized study, Phase 3b trial evaluating switching to once-daily elvitegravir-cobicistat-tenofovir DF-emtricitabine from twice daily raltegravir plus tenofovir DF-emtricitabine

- **Inclusion Criteria (n = 48)**
  - HIV RNA < 50 copies/mL
  - On RAL+ TDF-FTC for ≥ 6 months
  - Not taking any other ART
  - No new AIDS-defining conditions

- **Treatment Arms**
  - Switch to EVG-COBI-TDF-FTC

Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine GS-236-0123: Design

Virologic Response After Switch to EVG-COBI-TDF-FTC

# Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine GS 236-0123 Study: Common Adverse Events

<table>
<thead>
<tr>
<th>Adverse Event (treatment emergent)</th>
<th>Switched to EVG-COBI-TDF-FTC (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>21%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>13%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>10%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>10%</td>
</tr>
</tbody>
</table>

**Conclusion**: “All participants switching to 1 tablet once-a-day elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (*Stribild*) from a twice-daily raltegravir + emtricitabine/tenofovir disoproxil fumarate regimen remained virologically suppressed. *Stribild* was well tolerated. Switching to *Stribild* may be a viable option for virologically suppressed patients wanting to simplify from a twice-daily raltegravir-containing regimen.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.